checkmate 214: patterns of progression with nivolumab plus ipilimumab versus sunitinib for rcc
Published 3 years ago • 528 plays • Length 5:10Download video MP4
Download video MP3
Similar videos
-
4:13
checkmate 214: nivolumab ipilimumab vs sunitinib for advanced or metastatic renal cell carcinoma
-
11:58
checkmate 214: nivolumab ipilimumab or sunitinib in patients with advanced renal cell carcinoma
-
2:30
checkmate 214 trial update
-
4:23
first-line therapy options for rcc: lessons from checkmate 214 and keynote-427
-
1:33
checkmate 920: nivolumab plus ipilimumab for renal cell cancer
-
1:54
checkmate 214 trial in rcc updates
-
6:26
session 5: nivolumab cabozantinib vs sunitinib for advanced rcc | checkmate9er & checkmate214
-
2:01
michael atkins, md, discusses checkmate-214 investigating nivolumab ipilimumab in rcc patients
-
1:30
targeted therapies for the treatment of mrcc after nivolumab-ipilimumab failure
-
13:10
asco gu24 special: prof. nizar tannir shares checkmate 214 results
-
2:38
checkmate 9er: cabo-nivo superior to sunitinib in extended follow-up results
-
6:16
treatment-free survival results of nivolumab and salvage nivolumab ipilimumab for accrcc
-
3:09
should sunitinib still be used in the treatment of metstatic kidney cancer?
-
5:26
mrcc: impact of cabosun and checkmate-214
-
1:20
renal cell carcinoma: the emulsion and checkmate 214 trials
-
4:01
checkmate 9er trial: nivo cab vs sun 1l in advanced rcc
-
3:07
checkmate-214: nivolumab/ipilimumab for mrcc?
-
6:01
metastatic rcc: using frontline ipilimumab/nivolumab
-
2:34
nivo cabozantinib vs sunitinib for first-line treatment of arcc